ACADIA Pharmaceuticals
ISIN US0042251084
|WKN 603035
Overview
Description
ACADIA Pharmaceuticals, Inc. engages in the development and commercialization of medicines for central nervous system disorders. Its products include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.
Healthcare Biopharmaceuticals System-Specific Biopharmaceuticals United States
Financials
Key metrics
| Market capitalisation, EUR | 2,418.16 m |
| EPS, EUR | 1.26 |
| P/B ratio | 3.67 |
| P/E ratio | 11.84 |
| Dividend yield | 0.00% |
Income statement (2024)
| Revenue, EUR | 885.46 m |
| Net income, EUR | 209.35 m |
| Profit margin | 23.64% |
What ETF is ACADIA Pharmaceuticals in?
There are 29 ETFs which contain ACADIA Pharmaceuticals. All of these ETFs are listed in the table below. The ETF with the largest weighting of ACADIA Pharmaceuticals is the First Trust NYSE Arca Biotechnology UCITS ETF Acc.
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH.
Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.
Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.
